Table of Contents
Chemotherapy Research and Practice
Volume 2011 (2011), Article ID 619321, 10 pages
http://dx.doi.org/10.1155/2011/619321
Review Article

Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections

Department of Infectious Diseases, University Medical Centre Ljubljana, Japljeva 2, 1525 Ljubljana, Slovenia

Received 19 November 2010; Accepted 23 January 2011

Academic Editor: Athanassios Tsakris

Copyright © 2011 Kristina Nadrah and Franc Strle. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. G. Fowler, H. W. Boucher, G. R. Corey et al., “Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus,” The New England Journal of Medicine, vol. 355, no. 7, pp. 653–665, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. P. E. Pertel, P. Bernardo, C. Fogarty et al., “Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia,” Clinical Infectious Diseases, vol. 46, no. 8, pp. 1142–1151, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. A. Silverman, N. G. Perlmutter, and H. M. Shapiro, “Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 8, pp. 2538–2544, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. D. A. Enoch, J. M. Bygott, M. L. Daly, and J. A. Karas, “Daptomycin,” Journal of Infection, vol. 55, no. 3, pp. 205–213, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. K. Straus and R. E. W. Hancock, “Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides,” Biochimica et Biophysica Acta, vol. 1758, no. 9, pp. 1215–1223, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. J. K. Hobbs, K. Miller, A. J. O'Neill, and I. Chopra, “Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus,” Journal of Antimicrobial Chemotherapy, vol. 62, no. 5, pp. 1003–1008, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Cotroneo, R. Harris, N. Perlmutter, T. Beveridge, and J. A. Silverman, “Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 6, pp. 2223–2225, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Muthaiyan, J. A. Silverman, R. K. Jayaswal, and B. J. Wilkinson, “Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 3, pp. 980–990, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. K. L. LaPlante and M. J. Rybak, “Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 12, pp. 4665–4672, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. K. I. Udekwu, N. Parrish, P. Ankomah, F. Baquero, and B. R. Levin, “Functional relationship between bacterial cell density and the efficacy of antibiotics,” Journal of Antimicrobial Chemotherapy, vol. 63, no. 4, pp. 745–757, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. D. Appleman and D. M. Citron, “Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years,” Diagnostic Microbiology and Infectious Disease, vol. 66, no. 4, pp. 441–444, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. A. Silverman, N. Oliver, T. Andrew, and T. Li, “Resistance studies with daptomycin,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 6, pp. 1799–1802, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Steinkraus, R. White, and L. Friedrich, “Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–2005,” Journal of Antimicrobial Chemotherapy, vol. 60, no. 4, pp. 788–794, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. D. M. Anastasiou, M. Morgan, P. J. Ruane et al., “In vitro activity of daptomycin against multidrug-resistant Staphylococcus aureus and S. aureus with known virulence factors, including community-acquired methicillin-resistant isolates,” Diagnostic Microbiology and Infectious Disease, vol. 61, no. 3, pp. 339–342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Cha and M. J. Rybak, “Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations,” Diagnostic Microbiology and Infectious Disease, vol. 47, no. 3, pp. 539–546, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Friedman, J. D. Alder, and J. A. Silverman, “Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 6, pp. 2137–2145, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. G. W. Kaatz, T. S. Lundstrom, and S. M. Seo, “Mechanisms of daptomycin resistance in Staphylococcus aureus,” International Journal of Antimicrobial Agents, vol. 28, no. 4, pp. 280–287, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. I. L. B. da Cunha Camargo, H. M. Neoh, L. Cui, and K. Hiramatsu, “Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 12, pp. 4289–4299, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. S.-J. Yang, C. C. Nast, N. N. Mishra, M. R. Yeaman, P. D. Fey, and A. S. Bayer, “Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 8, pp. 3079–3085, 2010. View at Publisher · View at Google Scholar
  20. N. N. Mishra, S. J. Yang, A. Sawa et al., “Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 6, pp. 2312–2318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Cui, T. Isii, M. Fukuda et al., “A RpoB mutation confers dual hetero-resistance to daptomycin and vancomycin in Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 54, pp. 5222–5233, 2010. View at Google Scholar
  22. B. D. Duval, A. Mathew, S. W. Satola, and W. M. Shafer, “Altered growth, pigmentation, and antimicrobial susceptibility properties of Staphylococcus aureus due to loss of the major cold shock gene cspB,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 6, pp. 2283–2290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. W. E. Rose, S. N. Leonard, and M. J. Rybak, “Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 9, pp. 3061–3067, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. K. Pillai, H. S. Gold, G. Sakoulas, C. Wennersten, R. C. Moellering, and G. M. Eliopoulos, “Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 6, pp. 2223–2225, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Cui, E. Tominaga, H. M. Neoh, and K. Hiramatsu, “Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 3, pp. 1079–1082, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Jones, M. R. Yeaman, G. Sakoulas et al., “Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 1, pp. 269–278, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. T. Huang, C. H. Hsiao, C. H. Liao, C. W. Lee, and P. R. Hsueh, “Bacteremia and infective endocarditis caused by a non-daptomycin- susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan,” Journal of Clinical Microbiology, vol. 46, no. 3, pp. 1132–1136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Høiby, T. Bjarnsholt, M. Givskov, S. Molin, and O. Ciofu, “Antibiotic resistance of bacterial biofilms,” International Journal of Antimicrobial Agents, vol. 35, no. 4, pp. 322–332, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. J. C. Hageman, J. Patel, P. Franklin et al., “Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus,” Diagnostic Microbiology and Infectious Disease, vol. 62, no. 4, pp. 440–442, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. F. C. Tenover, S. W. Sinner, R. E. Segal et al., “Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy,” International Journal of Antimicrobial Agents, vol. 33, no. 6, pp. 564–568, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. J. W. Bennett, C. K. Murray, R. L. Holmes, J. E. Patterson, and J. H. Jorgensen, “Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus,” Diagnostic Microbiology and Infectious Disease, vol. 60, no. 4, pp. 437–440, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Sakoulas, J. Alder, C. Thauvin-Eliopoulos, R. C. Moellering, and G. M. Eliopoulos, “Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 4, pp. 1581–1585, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. P.-R. Hsueh, S.-Y. Lee, C.-L. Perng, T.-Y. Chang, and J.-J. Lu, “Clonal dissemination of meticillin-resistant and vancomycin-intermediate Staphylococcus aureus in a Taiwanese hospital,” International Journal of Antimicrobial Agents, vol. 36, no. 4, pp. 307–312, 2010. View at Publisher · View at Google Scholar
  34. S. K. Pillai, C. Wennersten, L. Venkataraman, G. M. Eliopoulos, R. C. Moellering, and A. W. Karchmer, “Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus,” Clinical Infectious Diseases, vol. 49, no. 8, pp. 1169–1174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. P. A. Moise, D. S. Smyth, N. El-fawal et al., “Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 1, pp. 85–90, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC), “Guidelines on the prevention , diagnosis , and treatment of infective endocarditis,” European Heart Journal, vol. 30, pp. 2369–2413, 2009. View at Google Scholar
  37. D. P. Levine and K. C. Lamp, “Daptomycin in the treatment of patients with infective endocarditis: experience from a registry,” American Journal of Medicine, vol. 120, no. 10, pp. S28–S33, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. J. A. Crompton, D. S. North, M. Yoon, J. N. Steenbergen, K. C. Lamp, and G. N. Forrest, “Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 8, pp. 1784–1791, 2010. View at Publisher · View at Google Scholar
  39. K. L. LaPlante and S. Woodmansee, “Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 9, pp. 3880–3886, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. B. T. Tsuji and M. J. Rybak, “Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin,” Diagnostic Microbiology and Infectious Disease, vol. 54, no. 1, pp. 73–77, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. J. M. Miró, C. García-de-la-Mària, Y. Armero et al., “Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin- resistant Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 10, pp. 4172–4177, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Lichterfeld, M. J. Ferraro, and B. T. Davis, “High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides,” International Journal of Antimicrobial Agents, vol. 35, no. 1, article 96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. J. L. Del Pozo and R. Patel, “Infection associated with prosthetic joints,” The New England Journal of Medicine, vol. 361, no. 8, pp. 787–794, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Zimmerli, A. Trampuz, and P. E. Ochsner, “Current concepts: prosthetic-joint infections,” The New England Journal of Medicine, vol. 351, no. 16, pp. 1645–1654, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. W. Zimmerli, A. F. Widmer, M. Blatter, R. Frei, and P. E. Ochsner, “Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial,” Journal of the American Medical Association, vol. 279, no. 19, pp. 1537–1541, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Singh, P. Ray, A. Das, and M. Sharma, “Penetration of antibiotics through Staphylococcus aureus and Staphylococcus epidermidis biofilms,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 9, pp. 1955–1958, 2010. View at Publisher · View at Google Scholar
  47. Z. Zheng and P. S. Stewart, “Penetration of rifampin through Staphylococcus epidermidis biofilms,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 3, pp. 900–903, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. P. S. Stewart, W. M. Davison, and J. N. Steenbergen, “Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 8, pp. 3505–3507, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Vaudaux, P. Francois, C. Bisognano, D. Li, D. P. Lew, and J. Schrenzel, “Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body due to Staphylococcus aureaus,” Journal of Antimicrobial Chemotherapy, vol. 52, no. 1, pp. 89–95, 2003. View at Google Scholar · View at Scopus
  50. M. Lefebvre, C. Jacqueline, G. Amador et al., “Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis,” International Journal of Antimicrobial Agents, vol. 36, no. 6, pp. 542–544, 2010. View at Publisher · View at Google Scholar
  51. A. K. John, D. Baldoni, M. Haschke et al., “Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 7, pp. 2719–2724, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. O. Murillo, C. Garrigós, M. E. Pachón et al., “Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 10, pp. 4252–4257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Garrigós, O. Murillo, G. Euba et al., “Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 12, pp. 5251–5256, 2010. View at Publisher · View at Google Scholar
  54. J. Parra-Ruiz, C. Vidaillac, W. E. Rose, and M. J. Rybak, “Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 10, pp. 4329–4334, 2010. View at Publisher · View at Google Scholar
  55. M. E. Olson, S. R. Slater, M. E. Rupp, and P. D. Fey, “Rifampicin enhances activity of daptomycin and vancomycin against both a polysaccharide intercellular adhesin (PIA)-dependent and -independent Staphylococcus epidermidis biofilm,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 10, pp. 2164–2171, 2010. View at Publisher · View at Google Scholar
  56. S.-J. Yang, Y. Q. Xiong, S. Boyle-Vavra, R. Daum, T. Jones, and A. S. Bayer, “Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the “seesaw effect”),” Antimicrobial Agents and Chemotherapy, vol. 54, no. 8, pp. 3161–3169, 2010. View at Publisher · View at Google Scholar
  57. K. H. Rand and H. J. Houck, “Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 8, pp. 2871–2875, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. J. M. Entenza, M. Giddey, J. Vouillamoz, and P. Moreillon, “In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin,” International Journal of Antimicrobial Agents, vol. 35, no. 5, pp. 451–456, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. M. E. Steed, C. Vidaillac, and M. J. Rybak, “Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 12, pp. 5187–5192, 2010. View at Publisher · View at Google Scholar
  60. M. De Gorgolas, P. Aviles, C. Verdejo, and M. L. F. Guerrero, “Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim- sulfamethoxazole and antibiotics that inhibit cell wall synthesis,” Antimicrobial Agents and Chemotherapy, vol. 39, no. 4, pp. 953–957, 1995. View at Google Scholar · View at Scopus
  61. S. Fujimura, T. Sato, T. Mikami, T. Kikuchi, K. Gomi, and A. Watanabe, “Combined efficacy of clarithromycin plus cefazolin or vancomycin against Staphylococcus aureus biofilms formed on titanium medical devices,” International Journal of Antimicrobial Agents, vol. 32, no. 6, pp. 481–484, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Sindelar, X. Zhao, A. Liew et al., “Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 12, pp. 3337–3343, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. X. Zhao and K. Drlica, “Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window,” Journal of Infectious Diseases, vol. 185, no. 4, pp. 561–565, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. A. A. Firsov, M. V. Smirnova, I. Y. Lubenko, S. N. Vostrov, Y. A. Portnoy, and S. H. Zinner, “Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model,” Journal of Antimicrobial Chemotherapy, vol. 58, no. 6, pp. 1185–1192, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. B. Quinn, S. Hussain, M. Malik, K. Drlica, and X. Zhao, “Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus,” Journal of Antimicrobial Chemotherapy, vol. 60, no. 6, pp. 1380–1383, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. B. T. Tsuji and M. J. Rybak, “Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 7, pp. 2735–2745, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. R. L. Akins and M. J. Rybak, “In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 7, pp. 1925–1929, 2000. View at Publisher · View at Google Scholar · View at Scopus
  68. B. Kuli, B. de Barbeyrac, F. A. Dauchy et al., “In vitro activities of daptomycin, tigecycline, linezolid and eight other antibiotics, alone and in combination, against 41 Staphylococcus spp. clinical isolates from bone and joint infections,” International Journal of Antimicrobial Agents, vol. 33, no. 5, pp. 491–493, 2009. View at Publisher · View at Google Scholar · View at Scopus